A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Dose Study of the Pharmacokinetics and Pharmacodynamics of Alogliptin 12.5 mg, 25 mg and 50 mg in Healthy Korean Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 06 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 Jul 2011 New trial record